key: cord-0729532-wcgc1ai6
authors: Barrett, Ravina
title: Reduced prescription tacrolimus use: A cross-sectional analysis of England’s national prescription statistics during COVID-19 pandemic by region.
date: 2020-06-25
journal: Kidney Int
DOI: 10.1016/j.kint.2020.06.010
sha: 2c2ad75ce4021869cf6f549a6fb1daf22456c7f9
doc_id: 729532
cord_uid: wcgc1ai6

nan

Many United Kingdom transplant centres currently provide restricted access due to COVID-19. 1 Full-year total organ transplants were 3997 in 2019/20 versus 4183 in the previous year, a fall of 4.45% as shown in table 1. Calcineurin Inhibitors like Tacrolimus prevent transplant rejection in kidney or liver recipients and withdrawal or tapering should be gradual to prevent transplant failure. 2 Oral tacrolimus should be prescribed and dispensed by brand to minimise inadvertent switching, associated with toxicity and graft rejection 3 . Tacrolimus modified release (MR) capsules are indicated once daily in adults.

Patients taking high doses of 1mg, 3mg and 5mg are vulnerable to harm (e.g. acute rejection of organ or graft) from abrupt withdrawal and are at increased risk of infections, including COVID-19, as they are immunosuppressed. Minimal prescription volume variation is expected as long-term community care can be pre-planned during lock-down in England.

The publicly available English Prescribing Dataset (EPD) 4 provides prescription data, which was used. This dataset excludes prescriptions in prisons, hospitals, private prescriptions and items prescribed but not dispensed nor reimbursed. To represent vulnerable patients, we focused on the high-dose MR formulations, but ignored ointments as these are predominantly used for cutaneous conditions.

We compared non-pandemic vs. pandemic data (March 2019 vs. 2020) of Advagraf® MR capsules (1mg, 3mg and 5mg) and Tacrolimus MR capsules (1mg and 3mg). We found in the pandemic, a fall in all high-dose MR formulations (see table 2) being prescribed. (-49%) . Similarly, Prograf 5mg fell to 250, from 350 (-29%), Adoport 5mg fell to 300, from 400 (-25%), Tacrolimus 1mg fell to 250, from 1,700 (-85%) and Modigraf 0.2mg sachets fell to 350, from 724 (-52%).

Regional variation was also noted with 370 prescriptions issued in 2019 vs. 351 prescriptions issued in 2020, a 5% fall (see figure 1 ). For medicines with 1000+ doses in the north, the increases were dramatic in 2020: Prograf 1mg (n=1,900 vs. 11,250, 592%), Adoport 1mg (n=1,650 vs. 5,200, 315%), Prograf 500microgram (n=550 vs. 2,750, 500%), Adoport 0.5mg (n=450 vs. 2,200, 489%), Advagraf 1mg MR (n=150 vs. 1,000, 667%).

We postulate some explanations: firstly, there are differences in prescribing policy by Clinical Commissioning Groups (CCGs), such that people entering lockdown were allowed prescriptions (of up to 6 months) by some primary-care organisations, but not others. Secondly, COVID-19 affected London and the South East approximately 10 days before the rest of the UK. Many surgeries were closed once an initial COVID-19 case was diagnosed and the administrative push towards online-care may have affects prescription issuance. Thirdly, sudden, and unexpected demands led to falls in medicines availability, as already stretched (by Brexit) supply chains became even more stretched. Thus, there are many factors that may have affected prescriptions. However, because of these reasons, there is a risk that vulnerable groups like transplant patients are disproportionately affected. Our concern is especially for those patients who do not have their medicines, who now cannot get the medicines from local or hospital pharmacies and or those patients who are unable to re-establish prescription issuance from their normal doctor(s). There is a risk that health inequalities along geographic and ethnic lines (40% of London residents are from ethnic minorities) maybe further exacerbated. In these times, incomplete implementation of the Falsified Medicines Directive (Directive 2011/62/EU) in Europe and the UK leaves us collectively vulnerable to falsified medicines entering the supply chain in response to medicines shortages.

Low prescription issuance of these important medicines during lockdown may have dire clinical implication for patients and may mean that organ transplants and donations that were so far successful, have been put at risk. This study represents a fraction of the cost invested in these patients, organs and procedures. Serious effort must be made immediately to identify these patients at surgery level and safeguard their health. 

Transplant centre closures and restrictions. ODT Clinical -NHS Blood and Transplant, /deceaseddonation/covid-19-advice-for-clinicians/transplant-centre-closures-and-restrictions

Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients

Oral tacrolimus products: reminder to prescribe and dispense by brand name only